Clinical Trials
Clinical trials are how new therapies get tested and, eventually, approved. If you have a MET-altered cancer, a trial may give you access to a treatment that isn’t yet available any other way, or that addresses resistance to a therapy you’re already on.
MET Crusaders can help you navigate your options directly. Our oncology nursing staff offers one-on-one support to help you understand your results, prepare for conversations with your oncologist, and identify trials or compassionate use programs that may be relevant to your situation. Contact us at info@metcrusaders.org or call 602-618-0183.
The Pipeline: MET Drugs in Development
New MET-targeted therapies are in development across all MET alteration types and multiple tumor types. The drugs listed below as approved have completed clinical testing and received FDA approval. The pipeline is what’s still in trials, moving toward approval. For MET-altered cancers, the most active areas of pipeline research right now are next-generation ADCs, combination regimens with existing MET TKIs, and drugs that address resistance to first-line MET therapies. To search for active trials that match your specific alteration, tumor type, and treatment history, use the Clinical Trials Search below.
Standard Drugs
These are FDA-approved MET-targeted therapies. Which ones may be appropriate depends on your specific alteration, tumor type, and treatment history. See the MET Therapies page for full descriptions and links to each drug’s patient-facing website.
Current MET Clinical Trials
Information coming soon.
Clinical Trials Search
MET Crusaders partners with Patient Data Vault, a platform that uses your health data to match your unique profile with clinical trials based on eligibility. Follow the link below to learn more and get started.
Access Pathways: Beyond Approved Therapies
Not every patient is a candidate for an approved therapy, or an approved therapy may stop working. These resources can help you and your oncologist explore what else may be available.
Lung-MAP is a clinical trial program that uses comprehensive genetic screening to match lung cancer patients to investigational treatments. Follow the link below to learn more.
Expanded Access (Compassionate Use) is a pathway that may allow patients with serious or life-threatening conditions to access investigational drugs outside of a clinical trial when no comparable approved treatment is available. Follow the link below to learn more.